Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA

BACKGROUND: We prospectively evaluated the efficacy and toxicity of a non‐platinum triplet regimen for patients with advanced non‐small cell lung cancer (NSCLC) expected to be platinum‐resistant. METHODS: Patients were diagnosed with NSCLC using endobronchial ultrasonography with a guide sheath as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemoto, Shinnosuke, Nakamura, Yoichi, Gyoutoku, Hiroshi, Senju, Hiroaki, Ogawara, Daiki, Ikeda, Takaya, Yamaguchi, Hiroyuki, Kitazaki, Takeshi, Nakano, Hirofumi, Nakatomi, Katsumi, Tomari, Shinya, Sato, Shuntaro, Nagashima, Seiji, Fukuda, Minoru, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397920/
https://www.ncbi.nlm.nih.gov/pubmed/30628188
http://dx.doi.org/10.1111/1759-7714.12958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397920/
https://www.ncbi.nlm.nih.gov/pubmed/30628188
http://dx.doi.org/10.1111/1759-7714.12958

Ejemplares similares